ACA
SEEL

Aptus Capital Advisors’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Aptus Capital Advisors’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3
Closed -$12.5K – 935
2023
Q2 		$12.5K Hold
3
– – ﹤0.01% 687
2023
Q1 		$7.24K Hold
3
– – ﹤0.01% 704
2022
Q4 		$7.11K Hold
3
– – ﹤0.01% 714
2022
Q3 		$10K Buy
+3
New +$11.8K ﹤0.01% 666

Other funds holding SEEL

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MWM
Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Aptus Capital Advisors's SEEL Position: Q3 2023 in Review

Aptus Capital Advisors sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q3 2023, closing a stake of 3 shares — an estimated $12.5K sold.

Aptus Capital Advisors first reported a position in SEEL in Q3 2022 and held it in 4 quarters. The position peaked at $12.5K in Q2 2023. 67 funds tracked by Wall St. Rank hold SEEL as of Q3 2023.

  • Aptus Capital Advisors reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Aptus Capital Advisors sold 3 Seelos Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $12.5K.
  • Aptus Capital Advisors first reported a position in Seelos Therapeutics, Inc. Common Stock in Q3 2022 and held it in 4 quarters.
  • Aptus Capital Advisors's Seelos Therapeutics, Inc. Common Stock position peaked at $12.5K in Q2 2023.
  • 67 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Aptus Capital Advisors's 13F filing for Q3 2023, filed 8 Nov 2023.